Hank Plain joined Morgenthaler Ventures in 2007 after more than 25 years in the life science industry, including co-founding eight medical device start-ups and directing the exits of six companies with a combined value in excess of $3 billion. He is based in Palo Alto, California and is focused on medical device investments.
In January 2011, Medtronic completed the acquisition of Ardian for $800 million, plus uncapped annual revenue growth milestones through Medtronic’s fiscal 2015. Hank is a founder, helped incubate Ardian at The Foundry and served as a director of the company.
In January 2010, Hank was a board member and on the deal committee that successfully negotiated the $785 million acquisition of Acclarent by Johnson & Johnson.
Hank is the Vice Chairman of The Foundry, the medical device incubator based in Menlo Park, California, where he co-founded Ardian, Cabochon Aesthetics, ForSight Labs, ForSight Vision2, Miramar and Transcend.
He also served as President and CEO of Perclose, Inc. from 1993 to 2000, when he led the company to $100 million in sales and managed the company’s successful IPO and acquisition in 1999 by Abbott Laboratories.
He was Chairman of Embolic Protection, where he helped negotiate the acquisition of the company in 2001 by Boston Scientific. He also served as a Director at TransVascular until Medtronic acquired the company in 2003. Previously, Hank worked at Eli Lilly for 12 years in various management positions.
Independent Board Director
Jan 1, 2012 - Current (almost 5 years)
Aug, 2007 - Current (about 9 years)
|Oct, 2014||Miramar Labs||$26.01M / Series D||Morgenthaler Ventures|
|Aug, 2014||Claret Medical||$18M / Series B||Lightstone Ventures|
|Apr, 2014||Holaira||$40M / Series D||Morgenthaler Ventures|
|Dec, 2012||Kona Medical||$10M / Series C||Morgenthaler Ventures|
|May, 2012||Kona Medical||$30M / Series C||Morgenthaler Ventures|
|Mar, 2009||Ardian||$47M / Series C||Morgenthaler Ventures|
|Mar, 2008||Miramar Labs||$20.3M / Series B||Morgenthaler Ventures|
|Nov, 2006||Ardian||$10.08M / Series B||Morgenthaler Ventures|
BS, Finance, General1980
|Aug 16, 2013||Xconomy - Biotech VCs, Stung by Startup Returns, Elbow into Royalty Financing|